When you click on the journal's content or open up the hard cover of Neurocritical Care, you expect to see something new or even something provocative. And yet there are less earth shaking issues. That is the hard truth, and it applies to all journals-great and small. Every editor would like to see the most original work by the most original study group, and only the journals with the highest impact factor can count on it. To publish an important first observation that may go on to become a landmark in the literature of neurocritical care is a lofty goal, but something we could work toward. Although the architect, Ludwig Mies van der Rohe, famously said ''It is better to be good than to be original'', in our continuously growing specialty, we have to be both.
Skeptics will point out that all concepts have been articulated before. Just go back far enough, and you will find it. They would say just look at renewed interest in the spreading depression already proposed by Leão in 1944-How about penicillin neurotoxicity now more often seen as cefepime neurotoxicity. I need not remind this readership that before we diagnosed cerebral salt wasting, we had SIADH and even before that-guess what-cerebral salt wasting.
Can we still be original? We should forcefully reject the ''everything has been done before'' argument. I continue to be pleasantly surprised by the highly interesting submissions over the years. In our field, advancement could come with a new original description, but this may also include an important rarity that has immediate consequences for management. There is no shortage of careful clinical descriptions of difficult patients, a new treatment, the first review of a major topic, and a never seen before neuroimage. We continue to publish papers that may seem a niche interest to some, but to others, their life's work.
Therefore, authors submitting material to the journal have noticed that although their papers are important observations, the work has been rejected because it lacks novelty. I have been rejecting papers that are not advancing our knowledge, are much of the same, and certainly studies that do nothing but confirming the obvious. Also, over the years, manuscripts have been rejected without external review. I have taken the liberty to reject papers that fail to meet our increasing higher standards, and papers that are clearly serving the interest of the industry. I have, to the best of my knowledge, not rejected a well-executed manuscript but reconsidered if I was wrong or too quick on the draw. In truth, the originality of a paper remains our most important measure. Editors would want to avoid significant time spent on very weak manuscripts.
Does this include case reports-the bane of journals? Case reports are rarely cited and may reduce impact factor if other worthwhile papers-that could be cited-are not published. Imagine a case that leads to a new concept or insight. We do not want to miss that.
So how could we define ''originality'' in a manuscript? Does it all have to be pristinely novel? What is synonymous with originality? One could say it should contain an innovative thought, a probing study into a new area, a rarely photographed or video-recorded clinical sign and even more closer to the bedside a validated new tool. Unoriginal does not need a definition, and we all recognize shopworn and uninspiring material.
Our journal has an important goal: to keep you up-to-date with the rapidly changing field. Our papers are increasingly more commonly cited by distinguished scholars, and that will sustain our quality. Only if we write original material will we thrive as academic neurointensivists.
This year, 2013, will be our 10th year of journal publishing; and it comes close after the 10-year celebration of the Neurocritical Care Society. We should be pleased with how the Journal is progressing. Over the last 10 years, we have seen a significant increase in the number of submissions, and there is no evidence of leveling off. You do not even have to be a neurointensivist to appreciate the journal, but you have to be eager to gather knowledge on how to care best for these unfortunate patients. I promise this year will see exciting new topics that will advance the care of our patients with acute neurologic and neurosurgical disease. Again I would like to thank the ad hoc reviewers listed below. It requires an effort and a commitment to the greater good to timely review papers, and these reviewers and the editorial board have been of great help identifying papers that are worth publishing.
